CC

ChemoCentryx

- NASDAQ:CCXI
Last Updated 2024-03-26

Indeed Snapshot

Track ChemoCentryx reviews on Indeed to uncover insights on employee sentiment
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 29th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 29th, 2022 11:40AM Aug 29th, 2022 11:40AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 28th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 28th, 2022 04:39AM Aug 28th, 2022 04:39AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 27th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 27th, 2022 03:59AM Aug 27th, 2022 03:59AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 25th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 25th, 2022 08:38AM Aug 25th, 2022 08:38AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 23rd, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 23rd, 2022 10:32AM Aug 23rd, 2022 10:32AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 21st, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 21st, 2022 12:15PM Aug 21st, 2022 12:15PM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 20th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 20th, 2022 01:52PM Aug 20th, 2022 01:52PM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 19th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 19th, 2022 12:15PM Aug 19th, 2022 12:15PM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 18th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 18th, 2022 03:59AM Aug 18th, 2022 03:59AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology
nasdaq:ccxi https://www.indeed.com/cmp/chemocentryx Aug 17th, 2022 12:00AM Open ChemoCentryx Pharmaceutical & Biotechnology ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives. As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing. Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives. 3.30 3.00 3.00 4.00 4.50 3.00 3.50 3.50 Aug 17th, 2022 09:38AM Aug 17th, 2022 09:38AM ChemoCentryx Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.